Market Newsdesk

CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares on the same terms and conditions. The offering is expected to close on May 9, 2025, subject to the satisfaction of customary closing conditions.

Canaccord Genuity is acting as sole bookrunner for the offering.

The public offering is being made pursuant to a shelf registration statement on Form S-3 (including a base prospectus) that was previously filed with the Securities and Exchange Commission (the “SEC”) on November 17, 2023, as amended on November 27, 2023, and declared effective by the SEC on November 29, 2023. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, can be obtained from Canaccord Genuity LLC, Attention: Syndication Department, 1 Post Office Square, Suite 3000, Boston, MA 02109, or by email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Exagen

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The Company’s flagship product, AVISE^® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE^®-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, please visit Exagen.com or follow @ExagenInc on X.

Forward-Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the completion of the public offering and other risks and uncertainties that are described under the heading “Risk Factors” in Exagen’s preliminary prospectus filed with the SEC on May 7, 2025, Exagen’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 11, 2025 and any subsequent filings with the SEC. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Ryan Douglas
Exagen Inc.
[email protected]
760.560.1525

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) — Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced the Company has completed its research program as part of the Israel Innovation Authority’s MAGNET incentive program, the Human Robot Interaction Consortium (the “HRI Consortium”). This three-year program provides research and collaboration grants to private businesses and leading academic centers, with the goal of “developing advanced technologies aimed at providing robots with social capabilities, enabling them to carry out various tasks and effective interactions with different users in diverse operational environments.”

Through its work with the HRI Consortium, Lifeward examined how artificial intelligence (“AI”) could be utilized with future generations of its ReWalk Personal Exoskeleton. The Company successfully demonstrated a proof-of-concept prototype that integrated advanced sensing technologies and AI to enable autonomous decision making to adapt to different use environments. This effort showed how AI can improve exoskeleton device usability and advance future iterations of the exoskeleton.

“Lifeward is honored to have participated in the HRI Consortium with other top minds in the robotics industry,” said Larry Jasinski, CEO of Lifeward. “There is enormous potential for AI to enhance and improve human-exoskeleton interactions in ways that are intuitive for users. Our goal is to provide exoskeletons that anticipate users’ intent and make the systems even easier to use. The exploration of incorporating innovative technologies and AI into future generations of the ReWalk is an important step toward that goal.”

“Throughout our three years working with the HRI Consortium, we’ve collaborated across sectors, combining Israel’s unique innovation ecosystem with our global clinical and commercial expertise to build systems that not only restore movement, but also intelligently support life in motion,” said David Hexner, Vice President of R&D at Lifeward. “We are grateful for the opportunity to work with the HRI Consortium, and are excited about opportunities to use AI, sensing technologies and machine vision to help revolutionize wearable robotics in the future.”

During the HRI Consortium, Lifeward collaborated with several universities and companies to develop advanced technologies aimed at improving the human-exoskeleton interaction. With top researchers in the fields of robotics, behavioral sciences, and human-computer interaction, this research seeks to widen adoption by making the use of exoskeletons easier, more natural and more broadly accepted. The HRI Consortium is a three-year project which started in May 2022 and concluded last month. Lifeward is one of six companies participating in the HRI Consortium, in addition to several Israeli universities.

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the ReStore Exo-Suit, and the MyoCycle FES System. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany.

Lifeward^®, ReWalk^®, ReStore^®, and Alter G^® are registered trademarks of Lifeward Ltd. and/or its affiliates.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company’s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company’s ability to have sufficient funds to meet certain future capital requirements, which could impair the Company’s efforts to develop and commercialize existing and new products; the Company’s ability to maintain and grow its reputation and the market acceptance of its products; the Company’s ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company’s limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company’s expectations as to its clinical research program and clinical results; the Company’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer; the Company’s ability to improve its products and develop new products; the Company’s compliance with medical device reporting regulations to report adverse events involving the Company’s products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company’s ability to market and sell its products; the Company’s ability to gain and maintain regulatory approvals; the Company’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company’s IT systems significantly disrupting its business operations; the Company’s ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading “Risk Factors” in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Lifeward Media Relations:

Kathleen O’Donnell
Vice President, Marketing & New Business Development
Lifeward Ltd.
E: [email protected]

Lifeward Investor Contact:

Mike Lawless
Chief Financial Officer
Lifeward Ltd.
E: [email protected]

MIGDAL HAEMEK, Israel, May 08, 2025 – Tower Semiconductor (NASDAQ/TASE: TSEM), the leading foundry of high-value analog semiconductor solutions, will participate in the 22^nd Annual Craig-Hallum Institutional Investor Conference in Minneapolis on Wednesday, May 28 and in the 53rd Annual TD Cowen Technology, Media & Telecom Conference in New York on Thursday, May 29. There will be an opportunity for investors to meet one-on-one with company representatives. Interested investors should contact the conference organizers or email the investor relations team at [email protected].

About Tower Semiconductor

Tower Semiconductor Ltd. (NASDAQ/TASE: TSEM), the leading foundry of high-value analog semiconductor solutions, provides technology, development, and process platforms for its customers in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical and aerospace and defense. Tower Semiconductor focuses on creating a positive and sustainable impact on the world through long-term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiPho, SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, displays, integrated power management (BCD and 700V), photonics, and MEMS. Tower Semiconductor also provides world-class design enablement for a quick and accurate design cycle as well as process transfer services, including development, transfer, and optimization, to IDMs and fabless companies. To provide multi-fab sourcing and extended capacity for its customers, Tower Semiconductor owns one operating facility in Israel (200mm), two in the U.S. (200mm), two in Japan (200mm and 300mm) which it owns through its 51% holdings in TPSCo, shares a 300mm facility in Agrate, Italy with STMicroelectronics as well as has access to a 300mm capacity corridor in Intel’s New Mexico factory. For more information, please visit: www.towersemi.com.

Contact Information:

Liat Avraham
Investor Relations
[email protected] | +972 4 650 6154

David Hanover
KCSA Strategic Communications

[email protected] | 212-682-6300

Attachment

• Tower Craig Hallum May 2025 Conferences PR FINAL

SINGAPORE, May 08, 2025 (GLOBE NEWSWIRE) — Primech AI Pte. Ltd. (“Primech AI” or the “Company”), a subsidiary of Primech Holdings Limited (Nasdaq: PMEC), today announced a significant expansion of its manufacturing capabilities through a strategic manufacturing partnership in Guangdong Province, China. The partnership will support the growing global demand for Primech AI’s innovative HYTRON bathroom cleaning robots, with plans to roll out 300 robots in the initial production phase.

The partnership establishes a comprehensive manufacturing framework with a well-established electronics manufacturer in Huizhou City of Guangdong Province, creating a robust production base to serve markets across Asia and beyond. This strategic location in China’s manufacturing heartland provides Primech AI access to a sophisticated electronics supply chain and specialized technical expertise.

“This manufacturing partnership in China represents a significant advancement in our production strategy,” said Charles Ng, Co-Founder and Chief Operating Officer of Primech AI. “The Guangdong region offers unparalleled advantages in electronics manufacturing infrastructure, component sourcing, and technical knowledge, enabling us to scale production efficiently while maintaining the highest quality standards for our HYTRON robots. Our ambitious target of rolling out 300 robots demonstrates our commitment to meeting market demand and accelerating our growth trajectory.”

Under the terms of the agreement, the manufacturing partner will manage the full production cycle for Primech AI’s HYTRON bathroom cleaning robots, including manufacturing and assembly based on Primech AI’s detailed specifications, implementation of comprehensive quality assurance protocols, performance of rigorous functionality and safety testing, securing necessary certifications to meet international regulatory requirements, and production scheduling and delivery timeline management. The manufacturing agreement covers an initial two-year period and includes provisions for regular quality monitoring, performance reporting, and collaborative development to ensure continuous improvement of manufacturing processes.

“Quality and reliability are foundational to our HYTRON technology, and our manufacturing partner in China brings extensive experience producing sophisticated electronic and robotic systems,” added Ng. “This collaboration allows us to leverage specialized manufacturing expertise while ensuring our exacting standards are maintained throughout the production process.”

The strategic location in China provides Primech AI with several key advantages. Access to a mature electronics manufacturing ecosystem enables efficient production scaling and quality control. The proximity to specialized component suppliers streamlines the supply chain and reduces procurement lead times. The facility offers scalable production capacity to meet the growing global demand for HYTRON robots, starting with the 300-unit initial target. Finally, the location provides efficient logistics for serving Asian markets, reducing shipping times and transportation costs.

This expansion of manufacturing capabilities in China complements Primech AI’s recent product innovations and market expansion initiatives, reinforcing the Company’s commitment to meeting growing global demand for its autonomous cleaning solutions.

About Primech AI

Primech AI is a leading robotics company dedicated to pushing the boundaries of innovation in technology. With a team of passionate individuals and a commitment to collaboration, Primech AI is poised to revolutionize the robotics industry with groundbreaking solutions that make a meaningful impact on society. For more information, visit www.primech.ai.

About Primech Holdings Limited

Headquartered in Singapore, Primech Holdings Limited is a leading provider of comprehensive technology-driven facilities services, predominantly serving both public and private sectors throughout Singapore. Primech Holdings offers an extensive range of services tailored to meet the complex demands of its diverse clientele. Services include advanced general facility maintenance services, specialized cleaning solutions such as marble polishing and facade cleaning, meticulous stewarding services, and targeted cleaning services for offices and homes. Known for its commitment to sustainability and cutting-edge technology, Primech Holdings integrates eco-friendly practices and smart technology solutions to enhance operational efficiency and client satisfaction. This strategic approach positions Primech Holdings as a leader in the industry and a proactive contributor to advancing industry standards and practices in Singapore and beyond. For more information, visit www.primechholdings.com.    

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, for example, statements about completing the acquisition, anticipated revenues, growth, and expansion. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

Company Contact:
Email: [email protected]

Investor Relations Contact:

Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: [email protected]

• New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases.
  

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 08, 2025 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals”, “Conduit” or the “Company”) today announces the filing of a new composition of matter patent covering a novel solid form of AZD5904, a clinical-stage myeloperoxidase (MPO) inhibitor in the Company’s pipeline.

This novel solid form offers significantly enhanced solubility relative to previously studied forms of AZD5904. This improved solubility enables new formulations that were previously not feasible, better aligning the compound’s pharmacokinetics with targeted disease biology and patient needs. The filing represents a significant development for AZD5904, which previously had limited intellectual property coverage restricted to its use in idiopathic male infertility. This composition of matter patent now positions Conduit to potentially secure a new intellectual property runway for the asset of up to 20 years, enabling a renewed strategic focus on broader clinical development opportunities.

AZD5904, a highly potent and selective MPO inhibitor, was originally developed by AstraZeneca for multiple sclerosis and chronic obstructive pulmonary disease (COPD). In five Phase 1 clinical studies, the compound demonstrated robust target engagement with no major safety or tolerability concerns. Myeloperoxidase is a key oxidative enzyme implicated in a range of inflammatory and oxidative stress-related conditions. In preclinical human models of idiopathic male infertility (IMI), AZD5904 demonstrated significant positive effects on sperm function, with improvements in both motility and penetration. Globally, 15% of couples are infertile, with male infertility contributing to 50% of cases. With a current lack of effective treatments available, AZD5904 could enable a new therapeutic option for this recognized medical unmet need.

“This new patent application represents a meaningful advance in the life cycle of AZD5904, with composition of matter protection now in place, we have the ability to fully unlock the therapeutic and commercial potential of this compound, including through novel formulation strategies that better suit the underlying disease mechanisms,” said Dr. Andrew Regan, Chief Executive Officer of Conduit Pharmaceuticals.

Conduit expects the improved solid form of AZD5904 to play a central role in its clinical development strategy, not only in male infertility, but in additional indications where oxidative stress and MPO-driven inflammation contribute to disease pathology.

About Conduit Pharmaceuticals

Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. Andrew Regan and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit’s future results of operations and financial position, Conduit’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavours with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under “Risk Factors” therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.

Investors & Media:

[email protected] 

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading provider of commerce media solutions, and Rebuy Engine, a leading ecommerce personalization platform for Shopify brands, have announced a strategic partnership to launch Rebuy Ads powered by Fluent, a new product offering designed to help merchants further engage their customers while unlocking additional revenue at no cost.

Unparalleled Scale and Insights

Rebuy Engine is uniquely positioned to drive impact at scale, generating over $1 billion in new revenue for its 12,000+ active merchants each year. The partnership leverages Fluent’s AI-powered advertiser marketplace and extensive expertise in demand generation, and pairs that with Rebuy Engine’s deep integration with the Shopify ecosystem and growing partner network.

Rebuy Ads powered by Fluent is revenue-positive for merchants—no investment in new tools or services required. It’s a unique offering that pays merchants for adoption rather than charging them, ensuring a high-value, risk-free opportunity while also providing Fluent access to new audiences via Rebuy Engine’s extensive merchant network. This innovative approach is expected to drive rapid adoption and engagement within the Rebuy Engine merchant community and Shopify platform.

“We’re excited to launch a solution that gives our merchants new revenue opportunities,” said Rebuy Co-Founder, James Van Erck. “With this new offering, merchants can monetize the thank-you page and get paid through Rebuy Ads powered by Fluent. Fluent’s competitive positioning in commerce media and commitment to partner success make them an ideal partner for this new endeavor. We believe this partnership strengthens our focus on helping brands deliver personalized experiences, convert more traffic, and grow faster.”

Tim Lukens, President of Commerce Media at Fluent, stated, “Our proficiency in performance marketing drives measurable growth for our partners. We are thrilled to collaborate with Rebuy to bring an integrated and unique solution to the Shopify ecosystem—leveraging our expertise in customer acquisition and engagement to create a seamless, high-value opportunity for merchants. Rebuy’s expansive partner network and merchant-first approach align seamlessly with Fluent’s mission to deliver high-impact commerce media solutions at scale.”

Looking Ahead

The Fluent and Rebuy partnership marks a significant step in expanding monetization opportunities for merchants while reinforcing the companies’ mutual commitment to design-led innovation and growth. With the combined expertise of both companies, Rebuy Ads powered by Fluent is set to redefine how Shopify merchants engage with performance-driven advertising. For more information on Rebuy Ads powered by Fluent and partnership opportunities, visit https://www.rebuyengine.com/product/ads.

About Rebuy

Rebuy empowers Shopify stores of all sizes to deliver personalized shopping experiences designed to increase conversions, boost order values, and retain more customers using intelligent upsells, cross-sells, and post-purchase follow-ups. More than 12,000 of the fastest-growing brands on Shopify use Rebuy, including Olipop, Aviator Nation, Momofuku, Tecovas, and DIME Beauty.

About Fluent, Inc.

Fluent, Inc. (NASDAQ: FLNT) is a commerce media solutions provider connecting top-tier brands with highly engaged consumers. Leveraging exclusive ad inventory, robust first-party data, and proprietary machine learning, Fluent unlocks additional revenue streams for partners and empowers advertisers to acquire their most valuable customers at scale. Founded in 2010, Fluent uses its deep expertise in performance marketing to drive monetization and increase engagement at key touchpoints across the customer journey. For more insights, visit https://www.fluentco.com.

Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipate,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward-looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. Readers are also advised to consider the factors under the heading “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Report on Form 10-K, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q and other SEC filings. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact Information

Walter Frank
IMS Investor Relations
[email protected]